Tuesday, March 06, 2012 10:50:44 AM
But why! Where's the weak link in the process?
Lets give the benefit of the doubt to the company. If the process is slow, and management truly believes in the future, perhaps it's time to do some trimming.
Take one for the team so to speak.
What's the biggest expense associated with the adoption process? Salaries! $360,000 for a CEO of a start up? Specifically this CEO. WHY!!! What is it in his past, that makes him worth that much money.
Look at the average salary of CEO's who participate in early stage companies. Base,$150,000, plus a performance bonus.
You have a CFO making $225,000 and a chief commercialization officer making a similar amount. Just those 3 employees make 2 times what the company produces in revenues in a fiscal year.
This is your company. Not one of those 3 aforementioned employees
owns stock in CryoPort.
Lets give the benefit of the doubt to the company. If the process is slow, and management truly believes in the future, perhaps it's time to do some trimming.
Take one for the team so to speak.
What's the biggest expense associated with the adoption process? Salaries! $360,000 for a CEO of a start up? Specifically this CEO. WHY!!! What is it in his past, that makes him worth that much money.
Look at the average salary of CEO's who participate in early stage companies. Base,$150,000, plus a performance bonus.
You have a CFO making $225,000 and a chief commercialization officer making a similar amount. Just those 3 employees make 2 times what the company produces in revenues in a fiscal year.
This is your company. Not one of those 3 aforementioned employees
owns stock in CryoPort.
Recent CYRX News
- Cryoport to Report First Quarter 2026 Financial Results on May 4, 2026 • PR Newswire (US) • 04/20/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 10:32:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/26/2026 12:01:25 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/26/2026 12:00:50 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/26/2026 12:00:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 12:01:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 12:00:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 12:00:11 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/12/2026 08:17:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 10:10:46 PM
- Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results • PR Newswire (US) • 03/03/2026 09:05:00 PM
- Cryoport to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026 • PR Newswire (US) • 02/17/2026 01:00:00 PM
- Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series • PR Newswire (US) • 02/11/2026 01:30:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/05/2026 09:56:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/12/2025 10:30:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/10/2025 09:10:52 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/12/2025 07:15:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2025 07:33:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/04/2025 10:18:14 PM
- Cryoport Reports Third Quarter 2025 Financial Results • PR Newswire (US) • 11/04/2025 09:05:00 PM
- Cryoport Continues to Set New Benchmarks for the Global Regenerative Medicine Supply Chain • PR Newswire (US) • 10/30/2025 12:30:00 PM
